Stoke Therapeutics (NASDAQ:STOK) Stock Breaks Above 50 Day Moving Average – What’s Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $27.09 and traded as high as $27.75. Stoke Therapeutics shares last traded at $27.45, with a volume of 1,209,951 shares trading hands.

More Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: HC Wainwright modestly improved its FY2028 EPS estimate to a loss of $1.74 per share from a loss of $1.78, indicating a slightly smaller projected loss in that year. HC Wainwright Cuts Earnings Estimates for Stoke Therapeutics
• Neutral Sentiment: The company plans to present at investor conferences in November; the announcement does not provide new clinical or financial results. Stoke Therapeutics to Present at Upcoming Investor Conferences in November
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to a loss of $3.93 from $3.35 and its FY2027 estimate to a loss of $3.98 from $2.55. It also lowered its Q4 2026 estimate to a loss of $1.11 from $0.81. The larger projected losses are the clearest near-term negative for STOK. HC Wainwright Cuts Earnings Estimates for Stoke Therapeutics

Wall Street Analyst Weigh In

A number of analysts have issued reports on STOK shares. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Stoke Therapeutics in a research note on Friday, October 30th. JPMorgan Chase & Co. assumed coverage on Stoke Therapeutics in a research note on Friday, August 21st. They set an “overweight” rating and a $40.00 price target for the company. Canaccord Genuity Group lowered their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. Wedbush boosted their price target on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.17.

Stoke Therapeutics Trading Up 1.7%

The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -7.28 and a beta of 1.36. The company has a 50-day moving average of $27.09 and a 200-day moving average of $30.84.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Thursday, October 29th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.15). The company had revenue of $11.26 million during the quarter, compared to analyst estimates of $8.21 million. Stoke Therapeutics had a negative return on equity of 66.76% and a negative net margin of 862.07%. On average, research analysts expect that Stoke Therapeutics, Inc. will post -3.78 EPS for the current year.

Insider Buying and Selling

In related news, General Counsel Jonathan Allan sold 2,861 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $91,637.83. Following the sale, the general counsel owned 21,225 shares in the company, valued at $679,836.75. This represents a 11.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 1,051 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $26.16, for a total transaction of $27,494.16. Following the completion of the sale, the insider directly owned 19,059 shares in the company, valued at $498,583.44. This trade represents a 5.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 27,418 shares of company stock valued at $860,914 over the last quarter. 9.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Stoke Therapeutics during the second quarter worth about $192,307,000. Redmile Group LLC raised its position in Stoke Therapeutics by 3.2% during the first quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock valued at $135,584,000 after acquiring an additional 130,050 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Stoke Therapeutics by 13.7% in the second quarter. Wellington Management Group LLP now owns 3,519,301 shares of the company’s stock valued at $115,152,000 after acquiring an additional 423,601 shares during the period. Jupiter Topco LLC acquired a new position in Stoke Therapeutics in the second quarter valued at approximately $59,358,000. Finally, Janus Henderson Group PLC lifted its holdings in Stoke Therapeutics by 11.2% in the first quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company’s stock valued at $52,456,000 after acquiring an additional 161,848 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.